
Auris Medical has revealed promising new in vitro data for AM-301, its drug-free nasal spray, showing that the product could …

Auris Medical (NASDAQ: EARS) has announced that it has initiated enrolment for a new Phase III trial that will evaluate …
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations

